Evidence map›Paper›PMID 34677737›Full record

ArticleInternational journal of clinical oncology2022

Prognostic value of PSA bounce after definitive radiotherapy revisited.

Fumihiko Urabe, Takahiro Kimura, Hiroshi Sasaki, Kojiro Tashiro, Kosuke Iwatani, Manabu Aoki, Shun Sato, Hiroyuki Takahashi, Kenta Miki, Shin Egawa

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fumihiko UrabeDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan. furabe0809@gmail.com.ORCID http://orcid.org/0000-0002-2599-8183
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Hiroshi SasakiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kojiro TashiroDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kosuke IwataniDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Manabu AokiDepartment of Radiology, The Jikei University School of Medicine, Tokyo, Japan.
Shun SatoDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Hiroyuki TakahashiDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Kenta MikiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shin EgawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific antigen (PSA) bounce after definitive radiotherapy has been reported as a predictor of improved biochemical recurrence-free survival (BCRFS). We revisited this phenomenon to confirm its clinical impact on oncological outcomes in patients with long-term follow-up who were free of biochemical recurrence (BCR) at least 3 years after treatment. MATERIALS AND

methodsA total of 541 patients with localized, intermediate-risk prostate cancer underwent low-dose rate brachytherapy with iodine-125 seeds with or without supplemental external beam radiotherapy in combination. Neoadjuvant hormonal therapy was administered to 273 patients (50.5%) with a median duration of 3 months (range 1-108 months). PSA bounce was defined as ≥ 0.2 ng/ml increase above the interval PSA nadir, followed by a decrease below that value.

resultsThe median age was 69 years (range 49-90 years). The median follow-up duration was 102 months (range 36-205 months). One-hundred and fifty patients (27.7%) had PSA bounce with a median magnitude of 0.47 ng/ml (range 0.2-3.19 ng/ml). Age was significantly associated with the occurrence of PSA bounce [age: hazard ratio (HR) 0.95, 95% confidence interval (CI) 0.93-0.98]. It was found to be independently associated with a decreased risk for BCR (HR 0.29; 95% CI 0.12-0.69) and clinical progression (HR 0.44; 95% CI 0.95-0.98).

conclusionPSA bounce indicated a favorable BCRFS and clinical progression-free survival in patients who had been free of BCR for at least 3 years after definitive radiotherapy.

Indexed as

BrachytherapyProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedNeoadjuvant TherapyPrognosisProstate-Specific AntigenRadiotherapy DosageProstate-Specific AntigenBrachytherapyOncological outcomesProstate cancerPSA bounce

Identifiers

PMID34677737
OpenAlexW3205546836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.